A 125-Year-Old Drug Gets Its First Real Lupus Trial

Sirolimus isn't a new drug. It was first approved in 1999 to prevent organ rejection after kidney transplants, and doctors have used it off-label in lupus for years based on small, uncontrolled studies and general immunology reasoning: it blocks a cellular pathway called mTOR that plays a role in how overactive immune cells multiply and misbehave. What lupus has never had, until now, is a real double-blind, placebo-controlled trial proving that this idea actually works in practice.

That gap was filled by the SIRIUS trial, a multicenter, randomized, placebo-controlled Phase 3 study conducted at six centers across China in patients with active systemic lupus erythematosus (SLE) whose disease was not adequately controlled by standard treatment. Seventy patients were randomized to add sirolimus or placebo on top of their existing standard-of-care therapy. Results were presented at the EULAR 2026 congress and reported by Medscape in June 2026, with lead investigator Dr. Mengtao Li of Peking Union Medical College Hospital in Beijing.

The findings were clear: 52.9% of patients who received sirolimus achieved a meaningful clinical response (measured by the SLE Responder Index, or SRI-4) at 24 weeks, compared with just 22.7% of patients on placebo. That difference was statistically significant, and the trial reported improvement in both clinical symptoms and the blood markers doctors use to track lupus activity, not just one or the other.

What makes this notable isn't just the result itself, it's what sirolimus is. Unlike most newly approved lupus therapies, which tend to be expensive biologic infusions or injections, sirolimus is an inexpensive, generic oral pill that's been manufactured and studied for a quarter century in a completely different patient population. If these results hold up and lead to broader use, it could offer a genuinely affordable add-on option in a disease area where cost and access are real, persistent barriers for a lot of patients.

That said, this is one trial from centers in China, and sirolimus is not without its own risks, including effects on wound healing, cholesterol, and infection risk, that your care team would need to weigh carefully against your specific health picture. It's also being added on top of standard care rather than replacing it. Still, having rigorous, randomized evidence behind a drug this well understood and this inexpensive is a meaningful addition to the lupus treatment conversation.

If your lupus hasn't responded fully to your current regimen, this is a reasonable one to ask your rheumatologist about, particularly if cost or access to newer biologics has been a barrier for you.